Therapy Detail

Therapy Name AC480
Synonym
Therapy Description

AC480 is an inhibitor of EGFR and ERBB2 (HER2), which may prevent downstream signaling and inhibit the proliferation of tumor cells that overexpress these receptors (PMID: 17062696).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
AC480 BMS-599626 EGFR Inhibitor (Pan) 42 HER2 Inhibitor 21 AC480 is an inhibitor of EGFR and ERBB2 (HER2), which may prevent downstream signaling and inhibit the proliferation of tumor cells that overexpress these receptors (PMID: 17062696).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 positive Advanced Solid Tumor predicted - sensitive AC480 Phase I Actionable In a Phase I clinical trial, AC480 (BMS-599626) treatment demonstrated preliminary clinical activity, resulting in stable disease as best response in 25% (11/44) of patients with advanced solid tumors, including patients expressing EGFR and/or ERBB2, with 2 patients achieving stable disease for greater than 6 months (PMID: 21576284). 21576284
Unknown unknown Advanced Solid Tumor not applicable AC480 Phase I Actionable In a Phase I trial, AC480 demonstrated safety and potential efficacy in patients with several solid tumor types (PMID: 21576284). 21576284
Clinical Trial Phase Therapies Title Recruitment Status